False pulse readings produced by the Oxevision patient monitoring system were reported to the British Standards Institution in 2023.

Overview Debates Related claims Topics Sources

Inquiry chair Kate Lampard is considering issuing interim regulations and recommendations regarding Oxevision camera technology to prevent further avoidable patient deaths.

In 2021, NHS England raised serious patient safety concerns regarding Oxevision's usage and capability claims with the Medicines and Healthcare products Regulatory Agency.

The Medicines and Healthcare products Regulatory Agency requested clinical evidence from manufacturer Lio Health supporting claims that Oxevision reduced self-harm, but Lio Health failed to provide it.

India's Ministry of Health launched the Strategy for Artificial Intelligence in Healthcare for India in February 2026 to govern data, validation, deployment, and monitoring.

India's Central Drugs Standard Control Organisation requires artificial intelligence developers to demonstrate clinical validity, demographic diversity in training datasets, version control, and post-market surveillance plans.

A report by the European Academies Science Advisory Council and the Federation of European Academies of Medicine recommended that high-risk artificial intelligence systems in healthcare remain under strict human supervision.

India's Central Drugs Standard Control Organisation issued guidance in July 2026 establishing approval pathways for Software in a Medical Device and Software as a Medical Device.

Regulatory sandboxes allow health authorities to evaluate rapidly evolving artificial intelligence technologies and balance patient safety against clinical innovation.

A joint report by European science academies proposed regulatory sandboxes as controlled, time-limited environments to test medical artificial intelligence tools under regulatory oversight before clinical deployment.

Sound Practice 10 of the Financial Stability Board's guidance establishes a risk-based intervention model requiring mandatory human sign-off for financial transactions exceeding specific thresholds.

The Financial Stability Board published 12 non-binding recommended practices on October 16, 2026, for the responsible adoption of artificial intelligence in financial institutions across G20 economies.

Bank of England Governor Andrew Bailey proposed pre- and post-deployment testing protocols for frontier AI models used in finance and G20-level agreements governing access to foreign-built frontier models.

The OCC, Federal Reserve Board, and FDIC plan a future request for information regarding bank AI model risk management, though no timeline has been set.

Sound Practice 12 expects financial institutions to secure contractual rights covering audit access, data portability, security incident notification, and orderly service termination before deploying externally sourced AI systems.

Updated Sound Practice 12 requires financial institutions to perform due diligence and maintain ongoing oversight of embedded AI functionality extending to fourth- and nth-party vendors.

Healthcare artificial intelligence pilots frequently stall when transitioning to production because clean static test datasets fail to account for live electronic health records and regulatory compliance requirements.

The Nolla Health pilot will operate in three stages, starting with 100 prescriptions reviewed by physicians before submission, followed by 400 prescriptions submitted by AI and reviewed retrospectively.

In the final stage of the Nolla Health pilot, prescriptions are fully automated by the AI, with a physician retrospectively reviewing at least 10% of the total monthly prescriptions.

Codametrix and Solventum stated they have integrated strict coding compliance guidelines and guardrails into their artificial intelligence systems to prevent inaccurate or fraudulent coding.

Health insurers are concerned that artificial intelligence billing tools are enabling upcoding to garner more reimbursement.